Should women receiving tamoxifen for breast cancer be screened for endometrial cancer?

Cancer Investigation

Volumn 18, Issue 8, 2000, Pages 796-797

  Barakat, R R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CELL DEATH; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; FEMALE; HUMAN; HYSTEROSCOPY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAMPLING; TRANSVAGINAL ECHOGRAPHY;

EID: 0033672030     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009012212     Document Type: Article

References (7)

1. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B- 14
2. The effect of tamoxifen on the endometrium
3. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features
4. Endometrial pathology at dilatation and curettage in breast cancer patients: Comparison of tamoxifen users and nonusers
5. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen
6. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
7. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen